NCT00364026已完成2 期
A Phase II Study to Evaluate the Effects of Darusentan on Safety and Efficacy in Subjects With Resistant Systolic Hypertension Receiving Combination Therapy With Three or More Antihypertensive Drugs, Including a Diuretic (Protocol DAR-201)
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 主要终点
- Co-primary efficacy measures are changes in trough sitting systolic BP from baseline through Weeks 8 and 10.
研究概览
简要总结
This is a research study of a new experimental drug called darusentan. Darusentan is not currently approved by the U.S. Food and Drug Administration (FDA) for use in the United States, which means that a doctor cannot prescribe this drug. The purpose of this study is to determine if darusentan is effective in reducing systolic blood pressure in subjects with resistant systolic hypertension, despite treatment with full doses of three or more blood pressure lowering drugs, including a diuretic.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 35 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects who are competent to provide written consent
- •Aged 35 to 85 years
- •Subjects with diabetes and/or chronic kidney disease must have a mean systolic blood pressure ≥130 mmHg
- •All other subjects must have a mean systolic blood pressure ≥140 mmHg
- •Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic
- •Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the time of Randomization.
排除标准
- •Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg at Screening
- •Serum ALT or AST >2X ULN
- •Subjects who have experienced myocardial infarction, unstable angina, or a cerebrovascular accident (CVA) within 6 month of the Screening Visit; or sick sinus syndrome or second or third degree atrioventricular block, chronic atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia
- •Implanted cardioverter defibrillator (ICD) that has fired for any arrhythmia within 3 months of Screening or implanted pacemakers
- •Symptomatic CHF requiring treatment
- •Hemodynamically significant valvular heart disease
- •Hemodialysis or peritoneal dialysis; or history of renal transplant
- •Diagnosis or recurrence of malignancy within the past 3 years
- •Sleep apnea
- •Subjects who perform alternating shift or night work
- •Subjects who have participated in a clinical study involving another investigational drug or device within 1 month of the Screening Visit
结局指标
主要结局
Co-primary efficacy measures are changes in trough sitting systolic BP from baseline through Weeks 8 and 10.
次要结局
- Secondary efficacy measurements are change in trough sitting diastolic BP from baseline to study Week 10; change in mean 24-hour systolic BP, as measured by ABPM; and the percent of subjects who reached systolic BP goal after 10 weeks of treatment.
研究者
相似试验
已完成
3 期
DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant HypertensionHypertensionNCT00330369Gilead Sciences352
终止
3 期
DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant HypertensionHypertensionNCT00353574Gilead Sciences282
已完成
2 期
Daridorexant to Prevent Delirium After Heart SurgeryPOSTOPERATIVE DELIRIUMPOSTOPERATIVE COGNITIVE DECLINENCT06630390University of Rochester11
终止
3 期
DORADO-AC-EX - A Long-Term Safety Extension Study to the Phase 3 DORADOC-AC Study (Protocol DAR-312) of Darusentan in Resistant HypertensionHypertensionNCT00389675Gilead Sciences661
已完成
2 期
A Clinical Trial of Durvalumab and Tremelimumab, Administered With Radiation Therapy or Ablation in Patients With Colorectal CancerMetastatic Colorectal CancerNCT03122509Memorial Sloan Kettering Cancer Center25